Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Ratios over time Q3 FY25 to Q2 FY26

Returns on capital

ROIC was 0.0% in Q2 FY26, the highest of these four quarters.

ROEROIC
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
ROE−189.9%−165.2%−144.0%−157.8%
ROIC0.0%0.0%0.0%0.0%

Debt

Net debt is 5.17× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Debt / equity0.0×0.0×0.0×0.0×
Net debt / EBITDA22.6×6.6×6.2×5.2×

Cash cycle, in days

Customers pay in 27 days, inventory is held 285 days and suppliers are paid in 633. Suppliers fund 321 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Cash cycle8611106−321
Days to pay suppliers−3342458422633
Days to be paid51224727

Per share, from Q3 FY25

Since Q3 FY25, per share: revenue has fallen 44.4%.

Revenue
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue1.0×0.8×0.9×0.6×
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(157.83%) (144.04%) (165.18%) (189.86%)

+8 more TTM periods

Piotroski F-Score
5 5 5 5
ROA
131.26% 119.06% 109.81% 107.44%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
301.38% 223.39% 262.71% 221.30%
Average Days of Receivables
27.43 247.29 12.24 5.32
Free Cash Flow per Share
(9.40) (5.28) (1.19) (4.18)
Free Cash Flow
(38.05) (21.38) (4.81) (16.88)
Capital Expenditures
— — (0.04) 0.03
Other line items
Cash ROIC
(61.68%) (37.86%) (6.69%) (14.81%)
Accounts Receivable Turnover
19.12 2.87 18.48 0.57
Accounts Payable Turnover
0.48 0.71 0.13 (0.78)
Inventory Turnover
1.19 1.35 0.16 (0.40)
Average Days of Payables
633.50 421.61 2,458.50 (333.86)
Days of Inventory on Hand
285.45 280.08 2,457.19 (253.30)
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
495.21% 294.50% 365.17% 278.56%
Selling, General and Administrative Expense of Revenue
599.39% 342.32% 430.26% 347.10%
Share Based Compensation of Revenue
86.33% 65.53% 102.11% 67.06%
Interest Coverage
(5.42) (5.02) (5.24) (4.61)
Operating CF/Net income
(0.21) (0.13) (0.03) (0.08)
Depreciation/Fixed assets
0.00 0.00 0.00 0.00
Capex/Depreciation
0.00 0.00 (0.06) 0.02
Revenue per Share
1.14 1.84 1.59 2.05
Operating CF per Share
(9.40) (5.28) (1.18) (4.18)
Capex per Share
0.00 0.00 (0.01) 0.01
Capex to Sales
0.00 0.00 0.01 0.00

Fold the line items

Columns are period end dates · fundamentals updated 25 Oct 2026